762 related articles for article (PubMed ID: 34734663)
1. Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous.
Rizvi SK; Chong BF
Dermatol Ther; 2022 Jan; 35(1):e15190. PubMed ID: 34734663
[TBL] [Abstract][Full Text] [Related]
2. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
3. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Kuhn A; Aberer E; Bata-Csörgő Z; Caproni M; Dreher A; Frances C; Gläser R; Klötgen HW; Landmann A; Marinovic B; Nyberg F; Olteanu R; Ranki A; Szepietowski JC; Volc-Platzer B
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):389-404. PubMed ID: 27859683
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cutaneous lupus.
Chang AY; Werth VP
Curr Rheumatol Rep; 2011 Aug; 13(4):300-7. PubMed ID: 21503694
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lupus erythematosus: update of therapeutic options part II.
Kuhn A; Ruland V; Bonsmann G
J Am Acad Dermatol; 2011 Dec; 65(6):e195-213. PubMed ID: 20800319
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
[TBL] [Abstract][Full Text] [Related]
8. [Systemic treatment of cutaneous lupus erythematosus].
Wenzel J; Bieber T; Uerlich M; Tüting T
J Dtsch Dermatol Ges; 2003 Sep; 1(9):694-704. PubMed ID: 16285276
[TBL] [Abstract][Full Text] [Related]
9. A review of the evidence and cost of therapies for cutaneous lupus erythematosus.
Rosen JD; Paul S; Maderal A
Lupus; 2019 Jun; 28(7):799-805. PubMed ID: 31042129
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous lupus erythematosus: diagnosis and management.
Fabbri P; Cardinali C; Giomi B; Caproni M
Am J Clin Dermatol; 2003; 4(7):449-65. PubMed ID: 12814335
[TBL] [Abstract][Full Text] [Related]
11. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Chasset F; Tounsi T; Cesbron E; Barbaud A; Francès C; Arnaud L
J Am Acad Dermatol; 2018 Feb; 78(2):342-350.e4. PubMed ID: 28989111
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study.
Pelka K; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M
Dermatol Ther; 2021 Jul; 34(4):e15013. PubMed ID: 34056799
[TBL] [Abstract][Full Text] [Related]
14. Immunogenetics of cutaneous lupus erythematosus.
Hersh AO; Arkin LM; Prahalad S
Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
[TBL] [Abstract][Full Text] [Related]
15. The different faces of cutaneous lupus erythematosus.
Renner R; Sticherling M
G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
[TBL] [Abstract][Full Text] [Related]
17. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.
Lu Q; Long H; Chow S; Hidayat S; Danarti R; Listiawan Y; Deng D; Guo Q; Fang H; Tao J; Zhao M; Xiang L; Che N; Li F; Zhao H; Lau CS; Ip FC; Ho KM; Paliza AC; Vicheth C; Godse K; Cho S; Seow CS; Miyachi Y; Khang TH; Ungpakorn R; Galadari H; Shah R; Yang K; Zhou Y; Selmi C; Sawalha AH; Zhang X; Chen Y; Lin CS
J Autoimmun; 2021 Sep; 123():102707. PubMed ID: 34364171
[TBL] [Abstract][Full Text] [Related]
18. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic approach and treatment of cutaneous lupus erythematosus.
Sticherling M; Bonsmann G; Kuhn A
J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433
[TBL] [Abstract][Full Text] [Related]
20. Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE).
Ogunsanya ME; Nduaguba SO; Brown CM
Lupus; 2018 Jun; 27(7):1107-1115. PubMed ID: 29514557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
